论文部分内容阅读
目的 :探讨抵抗素样分子β(resistin-like molecule beta,RELMβ)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其与临床病理特征的关系。方法:应用逆转录-聚合酶链反应(RT-PCR)方法和蛋白免疫印迹检测103例NSCLC组织及癌旁正常肺组织(其中65例具有配对的淋巴结转移标本)中RELMβ的表达情况,分析其表达与临床病理特征之间的关系。结果:RT-PCR和蛋白免疫印迹结果均显示,RELMβ在NSCLC组织中的表达明显高于正常肺组织。RELMβm RNA在肺癌组织中的表达(68.93%)显著高于癌旁组织(23.33%,P<0.05)。不同肿瘤的分化程度、TNM分期及淋巴结转移情况,RELMβ的表达强度不同,差异有统计学意义(P<0.05)。结论:RELMβ在NSCLC组织中异常高表达,与肺癌临床病理学特征相关,可能促进NSCLC的恶性进程。
Objective: To investigate the expression of resistin-like molecule beta (RELMβ) in non-small cell lung cancer (NSCLC) and its relationship with clinicopathological features. Methods: The expression of RELMβ in 103 NSCLC tissues and adjacent normal lung tissues (including 65 matched lymph node metastases) was detected by RT-PCR and Western blot. Relationship between expression and clinicopathological features. Results: The results of RT-PCR and Western blotting showed that the expression of RELMβ in NSCLC tissues was significantly higher than that in normal lung tissues. The expression of RELMβmRNA in lung cancer (68.93%) was significantly higher than that in paracancerous tissues (23.33%, P <0.05). Different tumor differentiation, TNM stage and lymph node metastasis, RELMβ expression intensity of different, the difference was statistically significant (P <0.05). CONCLUSIONS: RELMβ is highly expressed in NSCLC tissues and correlates with clinicopathological features of lung cancer, which may promote the malignant progression of NSCLC.